摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

[4-(5-cyano-2-methyl-6-oxo-1,6-dihydro-pyridin-3-yl)phenoxy]-acetic acid ethyl ester | 135334-89-3

中文名称
——
中文别名
——
英文名称
[4-(5-cyano-2-methyl-6-oxo-1,6-dihydro-pyridin-3-yl)phenoxy]-acetic acid ethyl ester
英文别名
ethyl 2-[4-(5-cyano-2-methyl-6-oxo-3-hydroperidyl)phenoxy]acetate;5-(4-carboethoxymethoxyphenyl)-6-methyl-2-oxo-1,2-dihydro-3-pyridinecarbonitrile;ethyl 2-[4-(5-cyano-2-methyl-6-oxo-1H-pyridin-3-yl)phenoxy]acetate
[4-(5-cyano-2-methyl-6-oxo-1,6-dihydro-pyridin-3-yl)phenoxy]-acetic acid ethyl ester化学式
CAS
135334-89-3
化学式
C17H16N2O4
mdl
——
分子量
312.325
InChiKey
NIANUYPKTNSJDV-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.3
  • 重原子数:
    23
  • 可旋转键数:
    6
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.24
  • 拓扑面积:
    88.4
  • 氢给体数:
    1
  • 氢受体数:
    5

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    [4-(5-cyano-2-methyl-6-oxo-1,6-dihydro-pyridin-3-yl)phenoxy]-acetic acid ethyl ester 在 lithium hydroxide 、 盐酸 作用下, 以 1,4-二氧六环 为溶剂, 反应 12.0h, 以64%的产率得到5-(4-carboxymethoxyphenyl)-6-methyl-2-oxo-1,2-dihydro-3-pyridinecarbonitrile
    参考文献:
    名称:
    [EN] DIHYDROPYRIDINE COMPOUNDS HAVING SIMULTANEOUS ABILITY TO BLOCK L-TYPE CALCIUM CHANNELS AND TO INHIBIT PHOSPHODIESTERASE TYPE 3 ACTIVITY
    [FR] COMPOSES DE DIHYDROPYRIDINE PRESENTANT A LA FOIS LA CAPACITE DE BLOQUER DES CANAUX CALCIQUES DE TYPE L ET LA CAPACITE D'INHIBER L'ACTIVITE DE TYPE 3 DE LA PHOSPHODIESTERASE
    摘要:
    本发明提供了具有对PDE-3和L型钙通道具有抑制活性的化合物。本发明还提供了包含这些化合物的药物组合物以及使用这些化合物治疗心血管疾病、中风、癫痫、眼科疾病或偏头痛的方法。
    公开号:
    WO2004033444A1
  • 作为产物:
    描述:
    5-(4-hydroxy-phenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carbonitrile溴乙酸乙酯 在 sodium hydride 作用下, 以 DMF (N,N-dimethyl-formamide) 为溶剂, 反应 2.25h, 以29%的产率得到[4-(5-cyano-2-methyl-6-oxo-1,6-dihydro-pyridin-3-yl)phenoxy]-acetic acid ethyl ester
    参考文献:
    名称:
    [EN] DIHYDROPYRIDINE COMPOUNDS HAVING SIMULTANEOUS ABILITY TO BLOCK L-TYPE CALCIUM CHANNELS AND TO INHIBIT PHOSPHODIESTERASE TYPE 3 ACTIVITY
    [FR] COMPOSES DE DIHYDROPYRIDINE PRESENTANT A LA FOIS LA CAPACITE DE BLOQUER DES CANAUX CALCIQUES DE TYPE L ET LA CAPACITE D'INHIBER L'ACTIVITE DE TYPE 3 DE LA PHOSPHODIESTERASE
    摘要:
    本发明提供了具有对PDE-3和L型钙通道具有抑制活性的化合物。本发明还提供了包含这些化合物的药物组合物以及使用这些化合物治疗心血管疾病、中风、癫痫、眼科疾病或偏头痛的方法。
    公开号:
    WO2004033444A1
点击查看最新优质反应信息

文献信息

  • [EN] DIHYDROPYRIDINE COMPOUNDS HAVING SIMULTANEOUS ABILITY TO BLOCK L-TYPE CALCIUM CHANNELS AND TO INHIBIT PHOSPHODIESTERASE TYPE 3 ACTIVITY<br/>[FR] COMPOSES DE DIHYDROPYRIDINE PRESENTANT A LA FOIS LA CAPACITE DE BLOQUER DES CANAUX CALCIQUES DE TYPE L ET LA CAPACITE D'INHIBER L'ACTIVITE DE TYPE 3 DE LA PHOSPHODIESTERASE
    申请人:ARTESIAN THERAPEUTICS INC
    公开号:WO2004033444A1
    公开(公告)日:2004-04-22
    The present invention provides compounds that possess inhibitory activity against PDE-3 and L-type calcium channels. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating cardiovascular disease, stroke, epilepsy, ophthalmic disorder or migraine.
    本发明提供了具有对PDE-3和L型钙通道具有抑制活性的化合物。本发明还提供了包含这些化合物的药物组合物以及使用这些化合物治疗心血管疾病、中风、癫痫、眼科疾病或偏头痛的方法。
  • Pyridone nitriles useful in treating cardiovascular disease
    申请人:Glaxo Inc.
    公开号:US05051431A1
    公开(公告)日:1991-09-24
    Pyridones of formula (I) for treating congestive heart failure: ##STR1## wherein: R.sup.1 and R.sup.2 are a variety of phenyl substituents, L is a divalent alkylene or amide containing alkylene linking group. Pharmaceutical composition, methods for their use in treating cardiovascular conditions, processes used in synthesis and intermediates used in such processes.
    公式(I)的吡啶酮化合物,用于治疗充血性心力衰竭:##STR1## 其中:R.sup.1和R.sup.2是各种苯基取代基,L是双价的烷基或含有烷基连接基的酰胺。制药组合物,用于治疗心血管疾病的方法,用于合成的过程和用于这些过程中的中间体。
  • Compounds having simultaneous ability to block L-type calcium channels and to inhibit phosphodiesterase type 3 activity
    申请人:ARTESIAN THERAPEUTICS, INC.
    公开号:US20040242648A1
    公开(公告)日:2004-12-02
    The present invention provides compounds that possess inhibitory activity against PDE-3 and L-type calcium channels. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating cardiovascular disease, stroke, epilepsy, ophthalmic disorder or migraine.
    本发明提供了具有对PDE-3和L型钙通道的抑制活性的化合物。本发明还提供了包含这种化合物的药物组合物和使用这种化合物治疗心血管疾病、中风、癫痫、眼科疾病或偏头痛的方法。
  • Compounds with mixed pde-inhibitory and beta-adrenergic antagonist or partial agonist activity for treatment of heart failure
    申请人:Hamilton S. Gregory
    公开号:US20070060748A1
    公开(公告)日:2007-03-15
    This invention provides compounds that possess inhibitory activity against β-adrenergic receptors and phosphodiesterase PDE, including phosphodiesterase 3 (PDE3). This invention further provides pharmaceutical compositions comprising such compounds; methods of using such compounds for treating cardiovascular disease, stroke, epilepsy, ophthalmic disorder or migraine; and methods of preparing pharmaceutical compositions and compounds that possess inhibitory activity against β-adrenergic receptors and PDE.
    本发明提供了一种具有对β-肾上腺素能受体和磷酸二酯酶PDE,包括磷酸二酯酶3(PDE3)的抑制活性的化合物。本发明还提供了包含这些化合物的药物组合物;使用这些化合物治疗心血管疾病、中风、癫痫、眼科疾病或偏头痛的方法;以及制备具有对β-肾上腺素能受体和PDE抑制活性的药物组合物和化合物的方法。
  • [EN] COMPOUNDS WITH MIXED PDE-INHIBITORY AND beta-ADRENERGIC ANTAGONIST OR PARTIAL AGONIST ACTIVITY FOR TREATMENT OF HEART FAILURE<br/>[FR] COMPOSES PRESENTANT UNE ACTIVITE MIXTE D'INHIBITION DE LA PDE ET D'ANTAGONISTE OU D'AGONISTE PARTIEL <supplemental>20041125</supplemental>EP0116948A2SYNTEX INC [US]198408291,27-29A1,25,37,40AEP0355583A2OTSUKA PHARMA CO LTD [JP]1990022872121X37XGB2190676ABRISTOL MYERS CO1987112510521165143X1,25,37XGB1465946ACIBA GEIGY AG19770302411311,23,12428mX1,25,37XEP0029992A1BOEHRINGER MANNHEIM GMBH [DE]198106101,92g,6hX1,25,37XDE2950479A1NATTERMANN A & CIE [DE]19810619811,32,3X1,25,37XUS5641783AKLEIN J PETER [US], et al19970624claims 1, 18 (column 97, line 5) and 21X1,25XGB1488330ASMITH KLINE FRENCH LAB19771012page 3, lines 32-37 and page 4, lines 1-16; claim 1X25,37XEP0138344A2SMITH KLINE FRENCH LAB [GB]19850424page 6, line 13- page 7, line 25X25,37XGB1567907ASMITH KLINE FRENCH LAB19800521page 5, lines 22-23; page 6, lines 51-52;X1XEGUCHI, YUKUO ET AL: "Studies on antiatherosclerotic agents. Synthesis of 7-ethoxycarbonyl-4-formyl-6,8-dimethyl-1(2H)-phthalazinone derivatives and related compounds", CHEMICAL & PHARMACEUTICAL BULLETIN , 39(3), 795-7 CODEN: CPBTAL; ISSN: 0009-2363, 1991, XP001194680EGUCHI, YUKUO ET ALStudies on antiatherosclerotic agents. Synthesis of 7-ethoxycarbonyl-4-formyl-6,8-dimethyl-1(2H)-phthalazinone derivatives and related compoundsCHEMICAL & PHARMACEUTICAL BULLETIN , 39(3), 795-7 CODEN: CPBTAL; ISSN: 0009-23631991compound 10 and table IX1,25,37XM.S. CHODNEKAR ET AL.: "Beta-Adrenergic blocking agents. 11. Heterocyclic analogs of pronethalol[2-isopropylamino-1-(2-naphthyl)ethanol]", JOURNAL OF MEDICINAL CHEMISTRY., vol. 15, no. 1, 1972, USAMERICAN CHEMICAL SOCIETY. WASHINGTON., pages 49 - 57, XP002292174M.S. CHODNEKAR ET AL.Beta-Adrenergic blocking agents. 11. Heterocyclic analogs of pronethalol[2-isopropylamino-1-(2-naphthyl)ethanol]JOURNAL OF MEDICINAL CHEMISTRY.USAMERICAN CHEMICAL SOCIETY. WASHINGTON.19721514957compound 30X37XGB1540628AOTSUKA PHARMA CO LTD197902141,83page 1, lines 6-24; examplesX1,25,37XCROWTHER A F ET AL: "BETA-ADRENERGIC BLOCKING AGENTS. 12. HETEROCYCLIC COMPOUNDS RELATEDTO PROPRANOLOL", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 15, no. 3, 1972, pages 260 - 266, XP000909966, ISSN: 0022-2623CROWTHER A F ET ALBETA-ADRENERGIC BLOCKING AGENTS. 12. HETEROCYCLIC COMPOUNDS RELATEDTO PROPRANOLOLJOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US19721530022-2623260266<table>VII</table>X37XDATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; NAKAGAWA, KAZUYUKI ET AL: "Carbostyril derivatives", XP002292176, retrieved from STN Database accession no. 1977:453098NAKAGAWA, KAZUYUKI ET ALCarbostyril derivativesCHEMABSCHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US1977:453098STNAabstract and compounds 61122-74-5, 61122-75-6, 63423-80-3, 63423-81-4X1,25,37XJPS51125291AOTSUKA PHARMA CO LTD19761101DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; NAKAGAWA, KAZUYUKI ET AL: "Carbostyril derivatives", XP002292177, retrieved from STN Database accession no. 1977:89632NAKAGAWA, KAZUYUKI ET ALCarbostyril derivativesCHEMABSCHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US1977:89632STNAabstract and compounds 61122-74-5 and 61122-75-6X1,25,37XJPS5168575AOTSUKA PHARMA CO LTD19760614DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; ISHIKAWA, HIROSHI ET AL: "Carbostyril derivatives", XP002292178, retrieved from STN Database accession no. 1978:509144ISHIKAWA, HIROSHI ET ALCarbostyril derivativesCHEMABSCHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US1978:509144STNAcompound 67358-84-3X1,25,37XJPS5350182AOTSUKA PHARMA CO LTD19780508DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; SAKANO, KAZUHISA ET AL: "3,4-Dihydrocarbostyril derivatives", XP002292179, retrieved from STN Database accession no. 1979:405123SAKANO, KAZUHISA ET AL3,4-Dihydrocarbostyril derivativesCHEMABSCHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US1979:405123STNAcompounds 70386-53-7, 70386-41-3, 63423-80-3X1,25,37XJPS5416478AOTSUKA PHARMA CO LTD19790207DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; "Carbostyrils", XP002292180, retrieved from STN Database accession no. 1982:406175CarbostyrilsCHEMABSCHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US1982:406175STNAcompound 81994-29-8X1,25XJPS5742673AOTSUKA PHARMA CO LTD19820310WO8402908A1POS LAB [FR]1984080213191,4X1,25,37XKIKKAWA, HIDEO ET AL: "The role of the seventh transmembrane region in high affinity binding of a .beta.2-selective agonist TA-2005", MOLECULAR PHARMACOLOGY , 53(1), 128-134 CODEN: MOPMA3; ISSN: 0026-895X, 1998, XP001199449KIKKAWA, HIDEO ET ALThe role of the seventh transmembrane region in high affinity binding of a .beta.2-selective agonist TA-2005MOLECULAR PHARMACOLOGY , 53(1), 128-134 CODEN: MOPMA3; ISSN: 0026-895X1998compounds II and III; abstractX1,25,37XDEYRUP, M. D. ET AL: "Structure-affinity profile of 8-hydroxycarbostyril-based agonists that dissociate slowly from the .beta.2-adrenoceptor", NAUNYN-SCHMIEDEBERG'S ARCHIVES OF PHARMACOLOGY , 359(3), 168-177 CODEN: NSAPCC; ISSN: 0028-1298, 1999, XP001199515DEYRUP, M. D. ET ALStructure-affinity profile of 8-hydroxycarbostyril-based agonists that dissociate slowly from the .beta.2-adrenoceptorNAUNYN-SCHMIEDEBERG'S ARCHIVES OF PHARMACOLOGY , 359(3), 168-177 CODEN: NSAPCC; ISSN: 0028-12981999compounds 10b, 10c, 10gX1,25,37XWO03015785A1ICOS CORP [US], et al20030227page 51, line 1, column 3PX1,25PXSIVAKUMAR, RAMAIYA ET AL: "Pharmacological evaluation of some new 1-substituted-4-hydroxy- phthalazines", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY , 37(10), 793-801 CODEN: EJMCA5; ISSN: 0223-5234, 2002, XP004393912SIVAKUMAR, RAMAIYA ET ALPharmacological evaluation of some new 1-substituted-4-hydroxy- phthalazinesEUROPEAN JOURNAL OF MEDICINAL CHEMISTRY , 37(10), 793-801 CODEN: EJMCA5; ISSN: 0223-52342002compounds 5, 7 and 12 and table 1PX1,25PX
    申请人:ARTESIAN THERAPEUTICS INC
    公开号:WO2004050657A3
    公开(公告)日:2004-11-25
查看更多

同类化合物

(S)-氨氯地平-d4 (R,S)-可替宁N-氧化物-甲基-d3 (R)-N'-亚硝基尼古丁 (5E)-5-[(2,5-二甲基-1-吡啶-3-基-吡咯-3-基)亚甲基]-2-亚磺酰基-1,3-噻唑烷-4-酮 (5-溴-3-吡啶基)[4-(1-吡咯烷基)-1-哌啶基]甲酮 (5-氨基-6-氰基-7-甲基[1,2]噻唑并[4,5-b]吡啶-3-甲酰胺) (2S)-2-[[[9-丙-2-基-6-[(4-吡啶-2-基苯基)甲基氨基]嘌呤-2-基]氨基]丁-1-醇 (2R,2''R)-(+)-[N,N''-双(2-吡啶基甲基)]-2,2''-联吡咯烷四盐酸盐 黄色素-37 麦斯明-D4 麦司明 麝香吡啶 鲁非罗尼 鲁卡他胺 高氯酸N-甲基甲基吡啶正离子 高氯酸,吡啶 高奎宁酸 马来酸溴苯那敏 马来酸左氨氯地平 顺式-双(异硫氰基)(2,2'-联吡啶基-4,4'-二羧基)(4,4'-二-壬基-2'-联吡啶基)钌(II) 顺式-二氯二(4-氯吡啶)铂 顺式-二(2,2'-联吡啶)二氯铬氯化物 顺式-1-(4-甲氧基苄基)-3-羟基-5-(3-吡啶)-2-吡咯烷酮 顺-双(2,2-二吡啶)二氯化钌(II) 水合物 顺-双(2,2'-二吡啶基)二氯化钌(II)二水合物 顺-二氯二(吡啶)铂(II) 顺-二(2,2'-联吡啶)二氯化钌(II)二水合物 非那吡啶 非洛地平杂质C 非洛地平 非戈替尼 非尼拉朵 非尼拉敏 阿雷地平 阿瑞洛莫 阿培利司N-6 阿伐曲波帕杂质40 间硝苯地平 间-硝苯地平 锇二(2,2'-联吡啶)氯化物 链黑霉素 链黑菌素 银杏酮盐酸盐 铬二烟酸盐 铝三烟酸盐 铜-缩氨基硫脲络合物 铜(2+)乙酸酯吡啶(1:2:1) 铁5-甲氧基-6-甲基-1-氧代-2-吡啶酮 钾4-氨基-3,6-二氯-2-吡啶羧酸酯 钯,二氯双(3-氯吡啶-κN)-,(SP-4-1)-